Volume-based predictive biomarkers of sequential FDG-PET/CT for sunitinib in cancer of unknown primary: identification of the best benefited patients
- 407 Downloads
To test the performance of sequential 18F-fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) in predicting survival after sunitinib therapies in patients with cancer of unknown primary (CUP).
CUP patients were enrolled for sequential PET/CT scanning for sunitinib and a control group. Univariate and multivariate analysis were applied to test the efficacy of sunitinib therapy in CUP patients. Next, sequential analyses involving PET/CT parameters were performed to identify and validate sensitive PET/CT biomarkers for sunitinib therapy. Finally, time-dependent receiver operating characteristic (TDROC) analyses were performed to compare the predictive accuracy.
Multivariate analysis proved that sunitinib group had significantly improved survival (p < 0.01) as compared to control group. After cycle 2 of therapy, multivariate analysis identified volume-based PET/CT parameters as sensitive biomarkers for sunitinib (p < 0.01). TDROC curves demonstrated whole-body total lesion glycolysis reduction (Δ WTLG) and follow-up WTLG to have good accuracy for efficacy prediction. This evidence was validated after cycle 4 of therapy with the same method.
Sunitinib therapy proved effective in treatment of CUP. PET/CT volume-based parameters may help predict outcome of sunitinib therapy, in which Δ WTLG and follow-up WTLG seem to be sensitive biomarkers for sunitinib efficacy. Patients with greater reduction and lower WTLG at follow-up seem to have better survival outcome.
KeywordsVolume-based PET/CT parameters Survival prediction Sunitinib Cancer of unknown primary
Compliance with ethical standards
This study was supported by the joint taking program of key disease (Grant 2014ZYJB0103) and the Shanghai Youth Science and Technology Talent Sailing Program (Grant 14YF1405900).
Conflicts of interest
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional review board and with the principles of the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards.
All patients gave informed consent to the treatment, PET/CT scanning and participation in study.
- 6.Greco FA, Hainsworth JD. Cancer of unknown primary site. In: DeVita Jr VT, Hellman S, Rosenberg SA, editors. Cancer: principles and practice of oncology. 8th ed. Philadelphia: Lippincott Williams & Wilkins; 2008. p. 2363–87.Google Scholar
- 17.Pfizer Inc. SUTENT, Summary of product characteristics.http://www.ema.europa.eu/humandocs/PDFs/EPAR/sutent/emea-combined-h687en.pdf July 2010.
- 20.Satoh et al. Whole-body total lesion glycolysis measured on fluorodeoxyglucose positron emission tomography/computed tomography as a prognostic variable in metastatic breast cancer. BMC Cancer. 2014,14:525.Google Scholar
- 22.Hyun SH, Choi JY, Kim K, Kim J, Shim YM, Um SW, et al. Volume-based parameters of 18F-fluorodeoxyglucose positron emission tomography/computed tomography improve outcome prediction in early-stage non–small cell lung cancer after surgical resection. Ann Surg. 2013;257(2):364–70.CrossRefGoogle Scholar
- 23.Cox DR. Regression models and life tables. J R Stat Soc. 1972;34:187–220.Google Scholar
- 26.Ma Y, Xu W, Liang Z, Li Y, Yu H, Yang C, Li J, Xiao J. Patient-oncologist Alliance and Psychosocial Well-being in Chinese Society Strongly Affect Cancer Management Adherence with Cancer of Unknown Primary. Psycho-oncology. 2016. doi: 10.1002/pon.4245.Google Scholar